Document is current
Any future updates will be listed below
-
Authors
Chen, Sophia Y.
Kung, Heng-Chung
Espinoza, Birginia
Washington, India
Chen, Kai
Mu, Kaiyi
Zlomke, Haley
Loycano, Michael
Wang, Rulin
Burns, William R.
Fu, Juan
Zheng, Lei
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01CA169702)
National Cancer Institute Specialized Programs of Research Excellence in Gastrointestinal Cancers (P50 CA062924)
Sidney Kimmel Comprehensive Cancer Center (P30 CA006973)
National Cancer Institute (5T32CA126607-12.)
Bristol-Myers Squibb (II-ON)
- License Information
-
More Information
Article History
Received: 20 December 2024
Accepted: 5 February 2025
First Online: 13 February 2025
Declarations
:
: All animal experimental procedures were approved by the local Institutional Animal Care and Use Committee (IACUC) and were conducted in accordance with the guidelines set by the Association for Assessment and Accreditation of Laboratory Animal Care.
: Not applicable.
: Lei Zheng receives grant support from Bristol-Meyer Squibb, Merck, AstraZeneca, and Abmeta. Lei Zheng is a paid consultant/Advisory Board Member at Biosion, Alphamab, NovaRock, Ambrx, Akrevia/Xilio, QED, Amberstone, Tavotek, Clinicaltrial Option, Duo Oncology, Histosonics, Fortress Biotech, and Mingruizhiyao. Lei Zheng holds shares at Alphamab, Amberstone, Mingruizhiyao, and Cellaration.
